Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Other Working Capital Changes (2024 - 2025)

Silence Therapeutics (SLN) has disclosed Other Working Capital Changes for 2 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes rose 7354.17% to $1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$6.0 million through Dec 2025, down 3546.06% year-over-year, with the annual reading at $110379.0 for FY2025, 75.9% down from the prior year.
  • Other Working Capital Changes hit $1.7 million in Q4 2025 for Silence Therapeutics, up from -$5.3 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $3.8 million in Q3 2024 to a low of -$5.3 million in Q3 2025.